Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26.

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

Collaborators (422)

Agnelli G, Berkowitz S, Bounameaux H, Büller HR, Cohen A, Gallus A, Lensing AW, Misselwitz F, Haskell L, Prins MH, Raskob G, Schellong S, Bauersachs R, van Bellen B, Boda Z, Borris L, Brenner B, Brighton T, Chlumsky J, Davidson B, Decousus H, Eriksson H, Jacobson B, Kakkar A, Kwong YL, Lee LH, Meijer K, van der Meer J, Minar E, Monreal M, Piovella F, Sandset PM, Smith M, Tomkowski W, Verhamme P, Wang Y, Wells P, Brandjes D, Mac Gillavry M, Otten HM, Prins MH, Carlsson A, Laporte S, Schulman S, Gent M, Turpie A, Martinelli I, Segers A, Davidson B, Lensing AW, Muhlhofer E, Tewes M, Trajanovic M, Muller K, Kim C, Gebel M, Benson A, Pap AF, Godrie J, Horvat-Broecker A, Spadari G, Peters-Wulf C, Roig J, Baker R, Bianchi A, Blombery P, Brighton T, Campbell P, Carroll P, Geraghty R, Chong B, Ramanathan S, Archis C, Coughlin P, Salem H, Crispin P, Dean M, Soni R, Denaro C, Kubler P, Coghlan D, Gallus A, Gan TE, Tran H, Coleman C, Jackson D, Khalafallah A, Leahy M, Leyden M, Leyden D, Sturtz C, McCann A, Gibbs H, McRae S, Richards B, Ward C, Curnow J, Baghestanian M, Erdogmus B, Samaha E, Nikoupayan-Mofrad M, Hirschl M, Sturm W, Kirchmair R, Marschang P, Drexel H, Mathies R, Pilger E, Brodmann M, Weltermann A, Buche M, Demelenne J, Gustin M, Hainaut P, Pothen L, de Leersnyder J, Motte S, Schroë H, Sprynger M, Verhamme P, Peerlinck K, Delcroix M, Vermassen F, Verstraeten P, Smet V, Vossaert R, van Bellen B, Panico M, Costa C, Blondal J, Kovacs M, Wells P, Rodger M, Carrier M, Wong T, Bi J, Chen Z, Chen R, Jing ZC, He J, Liu C, Liu S, Long S, Ma Y, Shao Y, Wang Y, Wang C, Yang YH, Xie C, Xu J, Ying K, Zhihong L, Chlumsky J, Hola D, Jirat S, Vitovec M, Kovářová K, Gilík J, Dosál J, Mandakova E, Matoška P, Podpera I, Podperova M, Spacek R, Urbanova R, Tuxen C, Sukles K, Pietila K, Vesanen M, Achkar A, Agraou B, Aquilanti S, Rifaï A, Berremili T, Brisot D, Brousse C, Tarodo P, Bura A, Amid-Lacombe C, Malloizel J, Boulon C, Alavoine L, Crestani B, Mismetti P, Buchmuller A, Accassat S, Elias A, Elias M, Emmerich J, Ferrari E, Guérin T, Beaka P, Lacroix P, Szwebel TA, Benhamou Y, de Maistre E, Falvo N, Mahe I, Meneveau N, Schiele F, Meyer G, Sanchez O, Planquette B, Mottier D, Le Moigne E, Couturaud F, Parent F, Pernod G, Imbert B, Elkouri D, Dary M, Queguiner A, Quere I, Galanaud JP, Roy PM, de Boisjolly-Bonnefoi JM, Schmidt J, Breuil N, Heuser S, Sevestre MA, Simoneau G, Bergmann JF, Stephan D, Trinh-Duc A, Gaillardou A, Grange C, Fassier T, Wahl D, Baron Von Bilderling P, Bauersachs R, Kuhlencordt P, Beyer-Westendorf J, Halbritter K, Werth S, Diehm C, Lawall H, Eifrig B, Espinola-Klein C, Weisser G, Giannitsis E, Haering HU, Hasslacher C, Herrmann T, Hoffmann U, Czihal M, Horacek T, Ibe M, Bauer A, Kieback A, Landgraf H, Lindhoff-Last E, Malyar N, Petermann W, Potratz J, Ranft J, Röcken M, Schellong S, Pomper L, Frommhold R, Schwaiblmair M, Berghaus T, Taute B, Lau YK, Tse E, Boda Z, Olah Z, Farkas K, Kolossváry E, Gurzó M, Kis E, Kovács A, Landi A, Lupkovics G, Pecsvarady Z, Riba M, Sipos G, Parakh R, Sembiring R, Barton J, Elias M, Goldstein L, Gavish D, Hoffman R, Hussein O, Inbal A, Lishner M, Elis A, Lugassy G, Varon D, Zeltser D, Rogowski O, Steinvil A, Zisman D, Ageno W, Ambrosio G, Cattaneo M, D'Angelo A, Ghirarduzzi A, Lotti M, Pierfranceschi MG, Lodigiani C, Martinelli I, Palareti G, Barone M, Beltrametti C, Porreca E, Prandoni P, Spiezia L, Quintavalla R, Cho WH, Ha JW, Kim HS, Park K, Sime I, Miliauskas S, Petrauskiene R, Sathar J, Beeker A, Ten Cate H, De Groot M, Kamphuisen P, Douma R, Kooy Mv, Coenen J, Meijer K, Mäkelburg A, Knol M, Tichelaar V, Harper P, Knottenbelt E, Ockelford P, Young L, Royle G, Simpson D, Chunilal S, Smith M, Ghanima W, Foyn S, Sandset PM, Tveit A, Abola MT, Adamiec R, Gorski P, Kloczko J, Lewczuk J, Nowak M, Musial J, Tomkowski W, Wronski J, Ng HJ, Adler D, Becker JH, Ellis G, Isaacs R, Bloy B, Allie R, Eckstein F, Jacobson B, van Rensburg JH, Schmidt S, Siebert H, Zyl L, Carrera M, Del Campo F, Diego I, Garcia-Bragado F, Jiménez D, Sánchez-Álvarez J, Redondo M, Roman Sanchez P, Villalta J, Eriksson H, Villegas-Scivetti M, Jonson T, Tygesen H, Lapidus L, Ottosson E, Själander A, Asmis L, Banyai M, Heidemann M, Baumgartner I, Bounameaux H, Righini M, Frank U, Hayoz D, Periard D, Chang WT, Chiu K, Wang KY, Weng ZC, Angchaisuksiri P, Pothirat C, Rojnuckarin P, Cohen A, Solis J, Hunt B, Luckit J, Albrecht C, Banish D, Feinbloom D, Botnick W, Chen D, Dexter J, Ettinger N, Gleeson J, Jaffer A, Joseph S, Kennedy M, Krell K, Lavender R, Lyons R, Moll S, Nadar V, Darrow K, Hardman V, Rathbun S, Rehm J, Rodriguez-Cintron W, Stevens K, Wright P, Ramaswamy M.

Abstract

BACKGROUND:

A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory monitoring. This approach may also simplify the treatment of pulmonary embolism.

METHODS:

In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months. The primary efficacy outcome was symptomatic recurrent venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding.

RESULTS:

Rivaroxaban was noninferior to standard therapy (noninferiority margin, 2.0; P=0.003) for the primary efficacy outcome, with 50 events in the rivaroxaban group (2.1%) versus 44 events in the standard-therapy group (1.8%) (hazard ratio, 1.12; 95% confidence interval [CI], 0.75 to 1.68). The principal safety outcome occurred in 10.3% of patients in the rivaroxaban group and 11.4% of those in the standard-therapy group (hazard ratio, 0.90; 95% CI, 0.76 to 1.07; P=0.23). Major bleeding was observed in 26 patients (1.1%) in the rivaroxaban group and 52 patients (2.2%) in the standard-therapy group (hazard ratio, 0.49; 95% CI, 0.31 to 0.79; P=0.003). Rates of other adverse events were similar in the two groups.

CONCLUSIONS:

A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile. (Funded by Bayer HealthCare and Janssen Pharmaceuticals; EINSTEIN-PE ClinicalTrials.gov number, NCT00439777.).

Comment in

PMID:
22449293
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Write to the Help Desk